Betathine

Betathine

A low-molecular-weight disulfide orphan agent which made it to clinical trials for treating myeloma, low-grade B-cell lymphoma, and metastatic melanoma. Its development was abandoned in 1999.
References in periodicals archive ?
Mice treated with BETATHINE experienced 100% survival after implantation with myeloma cells; 75% of non-treated animals died.
If active in humans, BETATHINE will represent a new paradigm in cancer therapy because rather than killing the cancer with toxins, BETATHINE is non-toxic and stimulates the body's own cancer fighting ability.
BETATHINE has been issued orphan drug status for multiple myeloma and metastatic melanoma by the U.
In contrast, the approved Phase I/II trials of BETATHINE will look directly at the ability of treatment to reduce cancer size, reduce cancer produced proteins, and modulate various immune parameters (cytokines and others).
The patent grants Dovetail exclusive rights to commercialize and market BETATHINE.
BETATHINE may someday be taken daily like a vitamin by nearly everyone as a health-promoting routine.
BETATHINE has been demonstrated in animal studies to be a potent anti-cancer agent.
In myeloma studies, BETATHINE administration resulted in a five-fold increase in the number of animals cured by Melphalan, the drug now used clinically to cause remissions in human myeloma.
BETATHINE demonstrated approximately equal effectiveness to Cyclophosphamide, the mainstay of current treatment of human breast cancer in the U.